Earnings reports from Celgene and Bristol-Myers show the importance of great science for pharma and biotech companies, according to Jim Cramer.
Another heavy day on the earnings front kept investors busy.
Facebook (FB) smashed earnings expectations--again. Shares are hitting record highs in the pre-market.
A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.
United Technologies is taking share from competitors like General Electirc.
DuPont shares were on the rise Tuesday following its latest quarterly results.
When your top line declines, it's harder to convince investors it's okay to wait years see if a partnership in an early-stage biotech company delivers a home-run drug.